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Prognostic Utility of Growth Differentiation
Factor-15 in Patients With Chronic Heart Failure
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Mariantonietta Cicoira, MD, PHD,§ Wolfram Doehner, MD, PHD,† Piotr Ponikowski, MD,
Gerasimos S. Filippatos, MD,# Piotr Rozentryt, MD,** Helmut Drexler, MD,*
Stefan D. Anker, MD, PHD,†‡ Kai C. Wollert, MD*
Hannover and Berlin, Germany; London, United Kingdom; Verona, Italy;
Wroclaw and Zabrze, Poland; and Athens, Greece
Objectives We explored the prognostic utility of growth differentiation factor (GDF)-15 in patients with chronic heart failure (CHF).
Background Growth differentiation factor-15 is a stress-responsive member of the transforming growth factor- cytokine su-
perfamily. It has recently been observed that patients with CHF have increased circulating levels of GDF-15. The
relations of GDF-15 to other biomarkers and to mortality in CHF have never been studied.
Methods Circulating levels of GDF-15 were determined by immunoradiometric assay in 455 patients with CHF with a me-
dian left ventricular ejection fraction (LVEF) of 32% (interquartile range 25% to 39%).
Results The median GDF-15 level was 1,949 ng/l (interquartile range 1,194 to 3,577); 74.9% of the patients presented
with GDF-15 levels 1,200 ng/l, the upper limit of normal in healthy elderly individuals. The GDF-15 levels were
closely related to New York Heart Association (NYHA) functional class and to amino-terminal pro–B-type natri-
uretic peptide (NT-proBNP). The risk of death during follow-up increased with increasing quartiles of GDF-15.
Mortality rates at 48 months were 10.0%, 9.4%, 33.4%, and 56.2% in the respective quartiles (p  0.001). After
adjustment for clinical variables and established biomarkers of adverse prognosis, including NT-proBNP, renal
dysfunction, anemia, and hyperuricemia, GDF-15 remained an independent predictor of mortality (adjusted haz-
ard ratio for 1 U in the Ln scale 2.26; 95% confidence interval 1.52 to 3.37; p  0.001). Growth differentiation
factor 15 provided prognostic information in clinically relevant patient subgroups (defined according to age, body
mass index, heart failure etiology, concomitant medical therapy, renal function, and the levels of hemoglobin
and uric acid) and added prognostic information to NYHA functional class, LVEF, and NT-proBNP.
Conclusions Growth differentiation factor 15 is a new biomarker of the risk of death in patients with CHF that provides prog-
nostic information beyond established clinical and biochemical markers. (J Am Coll Cardiol 2007;50:1054–60)
© 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.04.091a
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sisk stratification is important in patients with chronic
eart failure (CHF) and enables informed decisions about
reatment and end-of-life care. Clinical parameters, such as
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rognosis in cardiovascular disease. The first two authors contributed equally to this
ork.c
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ccepted April 1, 2007.dvanced age, higher New York Heart Association
NYHA) functional class, reduced left ventricular ejection
raction (LVEF), lower body mass index, renal dysfunction,
nd anemia have all been associated with poor outcomes in
HF (1–3). Moreover, metabolic markers, such as uric acid,
nd neurohormonal markers, including amino-terminal pro–
-type natriuretic peptide (NT-proBNP), provide prognostic
nformation (4,5).
See page 1061
Growth differentiation factor (GDF)-15 is a distant
ember of the transforming growth factor- cytokine
uperfamily and was first cloned as macrophage-inhibitory
ytokine 1 (6). Growth differentiation factor 15 expression
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September 11, 2007:1054–60 Prognostic Utility of GDF-15 in Heart Failures strongly up-regulated in cardiac myocytes by various
tressors, including reactive oxygen species, nitrosative
tress, and inflammatory cytokines (7). Whereas GDF-15 is
ot normally expressed in the myocardium, GDF-15 ex-
ression is induced in the heart in response to experimental
ressure overload and in mouse models of dilated cardio-
yopathy (8). Studies in GDF-15 gene–targeted mice have
hown that GDF-15 promotes antiapoptotic, antihypertro-
hic, and antiremodeling effects in the heart (7,8). Using a
ew immunoradiometric assay, we have recently observed
hat patients with CHF have increased circulating levels of
DF-15 (9).
Considering that GDF-15 may be a marker of multiple
tress pathways in the heart, we hypothesized that elevated
evels of GDF-15 provide prognostic information in CHF.
he objective of the present study was to explore the
rognostic utility of GDF-15 in patients with CHF in the
ontext of clinical characteristics and established prognostic
arkers.
ethods
tudy population and follow-up. We studied a cohort of
55 outpatients with CHF enrolled in Athens (Greece; n 
1), London (United Kingdom; n  89), Wroclaw/Zabre
Poland; n  95), and Verona (Italy; n  220). All of the
atients participated in projects designed to investigate
ovel biomarkers in CHF and provided written informed
onsent. The diagnosis of CHF was based on symptoms,
linical signs, and evidence of left ventricular enlargement
nd systolic functional impairment by echocardiography or
adionuclide or contrast ventriculography. All patients had a
istory of CHF for at least 6 months and were stable on
edication for at least 4 weeks before blood sampling.
atients with myocardial infarction within the preceding 12
eeks, known inflammatory or malignant disease, or creat-
nine levels 400 mol/l were excluded. After blood
ampling, patients were followed by outpatient assessments
nd telephone contact for a median of 40 months (inter-
uartile range 14 to 78 months). Survival status was cen-
ored on May 25, 2005 (May 31, 2006, in the Italian
ohort). No patient was lost to follow-up. The primary end
oint of the study was all-cause mortality. Information on
he cause of death was available in the Italian cohort. Nine
atients undergoing heart transplantation were censored
live at the time of the event. The institutional committees
n human research approved the protocol at all participating
tudy sites.
DF-15 immunoradiometric assay and other laboratory
nalyses. Serum samples were drawn after 10 min of rest
n a semirecumbent position for assessment of GDF-15 and
ther biomarkers. The GDF-15 concentrations were deter-
ined by immunoradiometric assay as previously described
9). All GDF-15 measurements were performed at Han-
over Medical School by investigators that were not aware
f patients’ characteristics and outcomes. The NT-proBNP levels were determined by a
hemiluminescence immunoassay
Roche Diagnostics, Mannheim,
ermany). Creatinine, hemoglo-
in, and uric acid measurements
ere performed at the participat-
ng study centers using standard
aboratory techniques. Creati-
ine clearance was calculated ac-
ording to the Cockcroft and
ault equation.
tatistical analyses. Data are
xpressed as absolute number
percentage), median (interquar-
ile range), or mean  standard
eviation as appropriate. The
olmogorov-Smirnov test was
sed to test for a normal distribution of continuous vari-
bles. Continuous variables were compared by Mann-
hitney test. Comparisons between strata of patients were
erformed by Kruskal-Wallis test or analysis of variance.
roportions were compared by using the chi-square test.
ultiple linear regression analysis was applied to identify
actors that were independently associated with GDF-15.
imple and multiple Cox regression analyses were used to
ssess prognostic associations. Data on body mass index and
reatinine clearance were available in 407 and 409 patients,
espectively; we therefore performed 2 sets of prespecified
nalyses, one that included these 2 parameters and one that
id not. Variables that were not normally distributed
GDF-15, NT-proBNP, creatinine, uric acid) were trans-
ormed to their natural logarithm for all regression analyses.
aplan-Meier plots were used to illustrate the timing of
vents during follow-up in relation to GDF-15 levels, and
tatistical assessment was performed by simple Cox regres-
ion analysis. For additional comparison of the prognostic
alues of GDF-15, NT-proBNP, creatinine, hemoglobin,
nd uric acid, receiver-operating characteristic (ROC)
urves were generated and c-statistics calculated. All anal-
ses were performed with StatView 5.0.1 (SAS Institute
nc., Cary, North Carolina), MedCalc 8.2.0.3 (MedCalc
oftware, Mariakerke, Belgium), or SAS 9.1 (SAS
nstitute).
esults
DF-15 levels and mortality in chronic heart failure.
he heart failure cohort consisted of 455 patients (90.5%
en) with a median age of 64 years (interquartile range
7 to 71 years). Baseline characteristics are summarized
n Table 1. The median GDF-15 level was 1,949 (1,194
o 3,577) ng/l; 74.9% of the patients presented with
DF-15 levels above 1,200 ng/l, the upper limit of
ormal in apparently healthy elderly individuals (9).
ecause the upper limit of normal corresponded to the
Abbreviations
and Acronyms
BNP  B-type natriuretic
peptide
CHF  chronic heart failure
GDF-15  growth
differentiation factor-15
LVEF  left ventricular
ejection fraction
NT-proBNP  amino-
terminal pro–B-type
natriuretic peptide
NYHA  New York Heart
Association
ROC  receiver-operating
characteristicower quartile boundary in patients, the patient material
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Prognostic Utility of GDF-15 in Heart Failure September 11, 2007:1054–60as stratified in quartiles (rounded cut-off limits 1,200,
,000, and 3,600 ng/l) when related to outcome. The
DF-15 levels were closely related to NYHA functional
lass and NT-proBNP (Fig. 1).
Out of 455 patients, 117 (25.7%) died during follow-up.
n the overall patient cohort, the 12-, 24-, and 48-month
atients’ Characteristics According to Quartiles of GDF-15
Table 1 Patients’ Characteristics According to Quartiles of GD
Qu
All Patients
(n  455)
<1,200
(n  114)
Clinical characteristics
Age (yrs) 64 (57–71) 58 (51–62)
Male gender 412 (90.5) 104 (91.2)
BMI (kg/m2)* 25.9 (23.5–29.0) 26.2 (24.2–29.3)
Ischemic etiology 308 (67.7) 62 (54.4)
Heart failure severity and
biomarkers
NYHA functional class 2.5  0.8 2.1  0.7
I 43 (9.5) 23 (20.2)
II 195 (42.9) 63 (55.3)
III 168 (36.9) 27 (23.7)
IV 49 (10.8) 1 (0.9)
LVEF (%) 32 (25–39) 35 (28–39)
NT-proBNP (ng/l) 801 (306–2308) 351 (162–606)
Creatinine (mol/l) 100.0 (86.6–126.0) 90 (81–99)
Crea Cl (ml/min)† 70.0 (51.2–89.8) 89 (77–103)
Hemoglobin (g/dl)‡ 13.9 (12.8–14.8) 14.2 (13.5–15.0)
Uric acid (mol/l)§ 400 (338–482) 340 (300–418)
Medication at study entry
ACE inhibitor/ARB 422 (92.7) 114 (100)
Beta-blocker 258 (58.6) 83 (80.6)
Diuretic 361 (79.3) 82 (71.9)
Spironolactone 108 (23.7) 23 (20.2)
ata from 455 patients are reported as number (percentage), median (interquartile range), or m
DF-15 and gender, etiology, and baseline medications were assessed by the chi-square test. The
elationships were tested by Kruskal-Wallis test.
ACE angiotensin-converting enzyme; ARB angiotensin receptor blocker; BMI body mass in
raction; NT-proBNP  amino-terminal pro–B-type natriuretic peptide; NYHA  New York Heart As
Figure 1 GDF-15 Levels in 455 Patients With Chronic Heart Fa
According to NYHA Functional Class or NT-proBNP Le
Patients were stratified according to New York Heart Association (NYHA) functiona
percentile, median, 75th percentile) and whisker (10th and 90th percentiles) plots
20 to 305 ng/l, in the second quartile from 306 to 800 ng/l, in the third quartile
0.001 by Kruskal-Wallis test in both panels. GDF-15  growth differentiation factoortality rates were 9.9%, 16.5%, and 24.6%, respectively.
here was a graded relationship between the level of
DF-15 at study entry and the risk of death during
ollow-up. The GDF-15 levels within the first and second
uartiles were associated with similar outcomes. The
DF-15 levels above the median (2,000 ng/l), however,
of GDF-15 (ng/l)
p Value
01 to 2,000
n  121)
2,001 to 3,600
(n  107)
>3,600
(n  113)
(57–70) 69 (60–73) 68 (62–74) 0.001
(88.4) 102 (95.3) 99 (87.6) 0.20
(24.1–29.0) 25.2 (23.5–29.4) 24.1 (21.9–28.2) 0.002
(67.8) 82 (76.6) 82 (72.6) 0.002
2.3  0.7 2.5  0.7 3.1  0.8 0.001
(9.9) 6 (5.6) 2 (1.8)
(50.4) 48 (44.9) 23 (20.4)
(35.5) 47 (41.1) 51 (45.1)
(4.1) 6 (5.6) 37 (32.7)
(25–39) 30 (25–37) 30 (22–38) 0.016
(238–1093) 1,020 (522–2408) 3,520 (1283–6768) 0.001
(84–110) 109 (93–132) 136 (96–161) 0.001
(58–95) 56 (48–75) 46 (35–68) 0.001
(13.2–14.8) 13.9 (13.0–14.7) 12.9 (11.6–14.4) 0.001
(300–450) 430 (370–500) 482 (379–589) 0.001
(95.9) 99 (92.5) 93 (82.3) 0.001
(60.7) 57 (54.8) 47 (42.3) 0.001
(79.3) 93 (86.9) 90 (79.6) 0.06
(20.7) 31 (29.0) 29 (25.7) 0.40
D. Data available from *407, †442, ‡449, §442, and 440 patients. The relationships between
nship between GDF-15 and NYHA functional class was assessed by analysis of variance. All other
ea Cl creatinine clearance; GDF growth differentiation factor; LVEF left ventricular ejection
n.
Stratified
t Study Entry
(A) or NT-proBNP quartiles (B). The GDF-15 levels are presented as box (25th
nt numbers are indicated. The NT-proBNP levels in the first quartile ranged from
01 to 2,307 ng/l, and in the fourth quartile from 2,308 to 88,300 ng/l. p 
T-proBNP  amino-terminal pro–B-type natriuretic peptide.F-15
artiles
1,2
(
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September 11, 2007:1054–60 Prognostic Utility of GDF-15 in Heart Failureere associated with markedly higher mortality rates
Fig. 2). Mortality rates at 48 months were 10.0% in the first
DF-15 quartile, 9.4% in the second quartile, 33.4% in the
hird quartile, and 56.2% in the fourth quartile. For com-
arison, mortality rates at 48 months according to NT-
roBNP quartiles at study entry were 6.1%, 13.0%, 29.3%,
nd 61.4%, respectively (p  0.001).
In the Italian cohort of 220 patients, 49 individuals died
uring follow-up (18 sudden deaths, 23 deaths from pro-
ressive heart failure). Nonsurvivors had higher GDF-15
evel at study entry than the survivors (2,197 [1,371 to
,008] ng/l vs. 1,338 [977 to 1,927] ng/l; p  0.001 by
ann-Whitney test). Compared with survivors, GDF-15
evels were also higher in patients who died suddenly (1,981
908 to 2,785] ng/l; p  0.035) or died from progressive
eart failure (2,646 [1,792 to 3,041] ng/l; p  0.001).
Figure 2 Cumulative Survival in 455 Patients With CHF
According to Quartiles of GDF-15 at Study Entry
The number of patients at risk and mortality rates are shown below the graph.
p  0.001 by simple Cox regression analysis. GDF  growth differentiation
factor.
Simple and Multiple Cox Regression Analysis fo
Table 2 Simple and Multiple Cox Regression
Characteristic
Simp
HR (95% CI)
Age (per 10 yrs) 1.48 (1.23–1.80
Male gender 1.55 (0.72–3.33
Ischemic etiology 1.40 (0.94–2.09
NYHA functional class (per class) 2.11 (1.65–2.70
LVEF (per 10% decrease) 1.77 (1.45–2.16
Ln NT-proBNP 1.89 (1.64–2.18
Ln creatinine 4.50 (2.72–7.47
Hb (per 1-g/dl decrease) 1.21 (1.08–1.36
Ln uric acid 5.93 (2.91–12.1
Ln GDF-15 3.09 (2.43–3.93
Complete data from 428 patients and all variables from the simple mo
GDF-15 were not normally distributed and were therefore transformed
these variables.
CI  confidence interval; Hb  hemoglobin; HR  hazard ratio; Ln  natussociation of GDF-15 with clinical and biochemical
actors. Increasing quartiles of GDF-15 were associated
ith age, a lower body mass index, ischemic etiology, higher
YHA functional class, and a lower LVEF (Table 1).
oreover, increased levels of GDF-15 were associated with
igher levels of NT-proBNP and uric acid, lower levels of
emoglobin, and reduced renal function (increased creati-
ine, reduced creatinine clearance) (Table 1). Patients with
levated levels of GDF-15 were less likely to be currently
reated with angiotensin-converting enzyme inhibitors/
ngiotensin receptor blockers or with beta-blockers (Table
). By multiple linear regression analysis using the natural
ogarithm of GDF-15 as the dependent variable, age (p 
.046), NYHA functional class (p 0.001), creatinine (p
.001), uric acid (p  0.011), NT-proBNP (p  0.001),
nd LVEF (p  0.001) were independently related to
DF-15. The r2 value of this model was 0.58.
DF-15 in the context of other markers of increased
ortality. By simple Cox-regression analysis, GDF-15,
dvanced age, higher NYHA functional class, reduced
VEF, increased levels of NT-proBNP, creatinine, and uric
cid, and reduced hemoglobin concentrations were associ-
ted with an increased risk of death during follow-up
Table 2). By multiple Cox regression analysis, GDF-15
p  0.001) and LVEF (p  0.001) emerged as the only
ndependent predictors of all-cause mortality (Table 2).
hen body mass index and creatinine clearance were
ncluded in the model, GDF-15 (p  0.001), LVEF (p 
.001), and NT-proBNP (p  0.013) independently pre-
icted all-cause mortality. Results were unchanged when
sing stratification of GDF-15 levels in quartiles. The ROC
urve analyses further illustrated that GDF-15 is a strong
ndicator of increased 1-year mortality, with a c-statistic of
.78, which was not significantly different (p  0.65) from
he c-statistic of NT-proBNP (0.79) but significantly (p 
.01) greater than the c-statistics of creatinine (0.64),
emoglobin (0.64), and uric acid (0.60). Combination with
DF-15 did not improve the c-statistic of NT-proBNP
ause Mortality
lysis for All-Cause Mortality
el Multiple Model
p Value HR (95% CI) p Value
0.001 1.16 (0.94–1.43) 0.17
0.26 1.74 (0.78–3.91) 0.18
0.10 0.98 (0.65–1.50) 0.94
0.001 1.12 (0.83–1.50) 0.46
0.001 1.65 (1.31–2.07) 0.001
0.001 1.17 (0.96–1.43) 0.13
0.001 1.55 (0.70–3.41) 0.28
0.009 1.05 (0.93–1.19) 0.41
0.001 0.96 (0.49–1.90) 0.92
0.001 2.26 (1.52–3.37) 0.001
e included in the multiple model. NT-proBNP, creatinine, uric acid, and
r natural logarithms. HRs refer to an increase of 1 U in the Ln scale inr All-C
Ana
le Mod
)
)
)
)
)
)
)
)
0)
)
del wer
to theiral logarithm; other abbreviations as in Table 1.
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Prognostic Utility of GDF-15 in Heart Failure September 11, 2007:1054–60combined c-statistic 0.79). The best GDF-15 level for
redicting 1-year mortality was 2,729 ng/l (sensitivity
5.0%, specificity 70.9%).
rognostic utility of GDF-15 in different patient sub-
roups. The prognostic value of GDF-15 was assessed in
everal patient subgroups (Fig. 3). The ROC curve-derived
DF-15 level of 2,729 ng/l was associated with an
ncreased risk of death in patient subgroups defined accord-
Figure 3 Risk of Death During Follow-Up Associated With a GD
Patient numbers are shown in parentheses. For analyses according to age, body m
study population were used to create subgroups of comparable size. Patients were
men, 12 g/dl in women), hyperuricemia (uric acid 400 mol/l), angiotensin-co
beta-blocker therapy at study entry. The hazard ratio (HR) could not be calculated
growth differentiation factor (GDF)-15 levels 2,729 ng/l, and 8 deaths in 21 pati
regression analysis. CI  confidence interval.
Figure 4 One-Year Mortality Rates According to NYHA Function
The number of deaths per number of patients is shown above each bar. For analy
used to create subgroups of comparable size. The p values were obtained by simp
tions as in Figures 1 and 3.ng to age, gender (trend in women only), body mass index,
eart failure etiology, renal function, medical therapy, and
he presence or absence of anemia or hyperuricemia.
In clinical practice, NYHA functional class and LVEF,
nd perhaps NT-proBNP (or BNP), are commonly used for
isk stratification in patients with stable CHF (10);
DF-15 added significant prognostic information to these
stablished risk markers (Fig. 4).
Level >2,729 ng/l at Study Entry
dex (BMI), creatinine, and creatinine clearance (Crea Cl), median values of the
stratified according to presence or absence of anemia (hemoglobin 13 g/dl in
g enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) therapy, and
ents not receiving ACEI/ARB therapy (there were 0 deaths in 12 patients with
ith GDF-15 levels 2,729 ng/l). The p values were obtained by simple Cox
ass, LVEF, NT-proBNP, and Levels of GDF-15
cording to LVEF and NT-proBNP, the median values of the study population were
regression analysis. LVEF  left ventricular ejection fraction; other abbrevia-F-15
ass in
also
nvertin
in pati
ents wal Cl
ses ac
le Cox
DT
r
p
a
t
a
G
p
p
t
h
a
a
a
c
h
(
o
d
N
l
C
a
s
p
o
h
a
(
G
s
L
t
N
L
G
p
p
b
i
i
F
t
e
G
a
i
i
G
s
i
s
p
f
f
i
s
c
s
o
l
i
G
H
n
u
p
p
l
p
L
a
C
G
r
l
(
s
s
G
c
t
c
R
A
n
w
R
1059JACC Vol. 50, No. 11, 2007 Kempf et al.
September 11, 2007:1054–60 Prognostic Utility of GDF-15 in Heart Failureiscussion
he present study identifies GDF-15 as a biomarker of
aised mortality in patients with CHF that provides inde-
endent prognostic information beyond established clinical
nd biochemical markers.
The GDF-15 levels were significantly increased in pa-
ients with CHF and displayed a graded relationship to
ll-cause mortality. By multiple Cox regression analysis,
DF-15 and LVEF emerged as the strongest independent
redictors of mortality. Growth differentiation factor 15
rovided prognostic information in clinically relevant pa-
ient subgroups defined according to age, body mass index,
eart failure etiology, renal function, and the presence or
bsence of anemia or hyperuricemia. Importantly, GDF-15
dded prognostic information to NYHA functional class
nd LVEF. Addition of GDF-15 did not improve the
-statistic of NT-proBNP. The c-statistic is regarded,
owever, as a somewhat insensitive measure of model fit
11). In fact, GDF-15 allowed stratifying patients with low
r high NT-proBNP levels into subgroups with markedly
ifferent mortality rates.
The GDF-15 levels were independently related to age,
YHA functional class, impaired renal function, uric acid
evels, a possible readout for metabolic abnormalities in
HF (5), and NT-proBNP, a marker of myocyte stretch,
nd hypertrophy (12), indicating that GDF-15 integrates
everal important clinical and biochemical indicators of a
oor prognosis in CHF. Together, these variables explained
nly part of the variation in the circulating GDF-15 levels,
ighlighting that additional, as yet undefined factors have
n impact on GDF-15. Given the pathobiology of GDF-15
8), and our observation that increasing quartiles of
DF-15 were associated with reduced LVEF, it was
omewhat surprising that GDF-15 was related to increased
VEF by multiple linear regression analysis. It is possible
hat other factors, such as NYHA functional class or
T-proBNP, carried the information provided by reduced
VEF in the multiple model. The relationship between
DF-15 and LVEF needs to be further explored in larger
atient populations.
Experimental studies suggest that GDF-15 levels may
rovide insight into a distinct pathophysiologic axis. It has
een shown that GDF-15 expression significantly increases
n the murine heart after various forms of stress, including
schemia-reperfusion injury and pressure overload (7,8).
urthermore, transgenic mice with dilated cardiomyopa-
hy, caused by overexpression of calcineurin or myocyte
nhancer factor 2C, display significant increases in
DF-15 expression levels in the heart (8). In these
nimal models, GDF-15 promotes protective effects by
nhibiting apoptosis, hypertrophy, and adverse remodel-
ng in the injured heart (7,8). The situation with
DF-15 is somewhat reminiscent of BNP, which is
ecreted from the heart in response to ischemia or
ncreases in wall stress, which is thought to promotealutary effects in animal models and which also provides
rognostic information in patients with CHF (12).
Although recent studies have highlighted important
unctional roles of GDF-15 in the heart and have defined,
or the first time, a functional role of GDF-15 in vivo (7,8),
t needs to be pointed out that GDF-15 is not a cardiac-
pecific cytokine. Other cell types besides cardiomyocytes
an produce GDF-15 in response to toxic or environmental
tress (13,14) and may possibly contribute to elevated levels
f GDF-15 in patients with CHF. Elevated circulating
evels of GDF-15 have been reported during pregnancy and
n patients with certain malignancies (15,16). Accordingly,
DF-15 cannot be used for the diagnosis of heart failure.
owever, like other important biomarkers in CHF that are
ot cardiac specific (e.g., renal dysfunction, anemia, hyper-
ricemia), measurement of GDF-15 can provide significant
rognostic information and pathophysiologic insight in
atients that have been diagnosed with CHF using estab-
ished criteria. Therefore, GDF-15 levels need to be inter-
reted in the context of cardiac-specific markers, such as
VEF or NT-proBNP, to arrive at an overall prognostic
ssessment.
onclusions
rowth differentiation factor 15 is a new biomarker of the
isk of death in patients with CHF. Although GDF-15
evels greater than the median (2,000 ng/l) or 2,729 ng/l
best ROC curve-derived cut-off level) were useful for risk
tratification in the present patient population, forthcoming
tudies need to further define appropriate cut-off levels for
DF-15 in CHF. Before considering implementation in
linical practice, it will be important to see if GDF-15 levels
rack changes in clinical status and whether GDF-15 levels
an help with therapeutic decision making.
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